Key result
Decisions regarding identifying an end-date-of-study and overlaps had the strongest impacts on measuring medication adherence across PDC with≥1, PDCwm, and DPPR.
Why the study?
Methods for measuring medication adherence are inconsistent, and few studies have compared the sensitivities of the effects of several criteria on adherence.
Observational (n=14,288)
Decisions regarding identifying an end-date-of-study and handling overlaps significantly impact the measurement of antihypertensive medication adherence using claims data.
Clinicians should interpret PDC-based adherence cautiously; this novel finding leaves open the need for standardized measurement protocols.
Purpose: Numerous studies have utilized various forms of adherence measures. However, methods for measuring adherence are inconsistent. Moreover, few studies are available that have compared sensitivities of the effects of several criteria on medication adherence. This study aims to compare measures of adherence using varied analytical decisions. Materials and Methods: We included three measures for adherence: proportion of days covered with one or more medications (PDC with≥ 1 ), duration weighted mean PDC (PDC wm ), and daily polypharmacy possession ratio (DPPR). We compared the sensitivities of the measures by changing parameters in the Korean nationwide claims database. First, we used PDC with≥ 1 as our base model. Then, we divided an adherence measure algorithm into three categories: (1) definition of data cleaning, (2) inclusion criteria and observation period, and (3) calculation methods of medication adherence. The categories included eight decision nodes that incorporated 25 alternative options. Finally, we assessed the medication adherence for the base-case with commonly used values and then varied to measure with each alternative option. Results: The base-case included 14,288 beneficiaries with antihypertensives. Among eight decisions, both handling an end-date-of-study and overlaps had the strongest impacts on measuring PDC with≥ 1 , PDC wm , and DPPR, with small differences in sample size. Instead of the estimates of adherence from PDC wm , those of PDC with≥ 1 and DPPR were similar. Furthermore, a tendency toward a higher medication adherence was observed with a smaller study population. Conclusion: The decisions regarding identifying an end-date-of-study and overlaps showed meaningful impacts of all three measures including PDC with≥ 1 , PDCwm, and DPPR on measuring medication adherence.
No takes yet. Share an insight, caveat, or question.
Choo et al. (2021) conducted an observational in Hypertension (n=14,288). Analytical decisions for measuring medication adherence vs. Base-case model was evaluated on Impact of analytical decisions on medication adherence measures (PDC with≥1, PDCwm, DPPR). Decisions regarding identifying an end-date-of-study and overlaps had the strongest impacts on measuring medication adherence across PDC with≥1, PDCwm, and DPPR.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: